Cabometyx (cabozantinib)

pCPA File Number: 21102
Negotiation Status:
Concluded with an LOI
Indication(s):
Renal Cell Carcinoma
Sponsor/Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
CDA-AMC Project Number:
PC0163-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: